ImmunityBio, Inc. reported $166M of revenue over the trailing twelve months, +193% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $166M (to Q2 2026). Net income: −$992M, trailing twelve months to Q2 2026. Free cash flow: −$288M, trailing twelve months to Q2 2026. Operating margin: −155%, trailing twelve months to Q2 2026.

IBRXImmunityBio, Inc.

Healthcare

$10.51+285% 1Y

$10.51

$1.9852 weeks$11.55

IBRX as reported

ImmunityBio, Inc. reported $166M of revenue over the trailing twelve months, +193% on the year before. 9 reported series are charted on this page, each one as filed.

$166M

Revenue, trailing twelve months · to Q2 2026 · +193% against the twelve months before

Net income: −$992M
Net income · +170% year on year · trailing twelve months to Q2 2026
Free cash flow: −$288M
Free cash flow · −19% year on year · trailing twelve months to Q2 2026
Operating margin: −155%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for IBRX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$166M	+193%	Q2 2026
Net income	−$992M	+170%	Q2 2026
EPS	−$0.97	+102%	Q2 2026
Gross margin	99%	n/a	Q2 2026
Operating margin	−155%	n/a	Q2 2026
Net margin	−563%	n/a	Q2 2026
ROE	82%	n/a	Q2 2026
ROA	−107%	n/a	Q2 2026
Free cash flow	−$288M	−19%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.